Maternal Diabetes and Early Neurodevelopment: Differential Risks Emerge Across Diabetes Types and Infant Sex
Posted inDiabetes & Endocrinology news Pediatrics

Maternal Diabetes and Early Neurodevelopment: Differential Risks Emerge Across Diabetes Types and Infant Sex

A nationwide cohort study of 466,462 infants reveals that maternal pregestational diabetes significantly increases the risk of delayed developmental milestones, with type 1 diabetes conferring the highest risk and female offspring showing particular vulnerability across language, personal-social, and gross motor domains.
Surgical Metabolic Intervention: Bariatric Surgery Transforms Outcomes in Type 1 Diabetes With Obesity
Posted inDiabetes & Endocrinology General Surgery news

Surgical Metabolic Intervention: Bariatric Surgery Transforms Outcomes in Type 1 Diabetes With Obesity

A multicenter retrospective cohort study reveals that metabolic bariatric surgery in 162 adults with type 1 diabetes and obesity achieved 29.7% weight loss at one year, reduced insulin requirements by 57%, and significantly improved glycemic and lipid profiles, suggesting MBS as a viable option for this high-risk population.
Blood Pressure Variability Emerges as Independent Predictor of Kidney Disease Progression in Type 1 Diabetes, with African Caribbean Ethnicity as Key Risk Factor
Posted inDiabetes & Endocrinology Nephrology news

Blood Pressure Variability Emerges as Independent Predictor of Kidney Disease Progression in Type 1 Diabetes, with African Caribbean Ethnicity as Key Risk Factor

A 14-year cohort study of 3,079 individuals with type 1 diabetes reveals that visit-to-visit blood pressure variability, particularly systolic blood pressure variability measured by average real variability, significantly predicts diabetic kidney disease progression. African Caribbean ethnicity emerged as an independent risk factor, with a 54% increased hazard per unit increase in systolic BP variability.
Lifestyle Determinants and Metabolic Compensation in Pregnancies Complicated by Type 1 Diabetes: A Synthesis of the ENDIA Study and Recent Evidence
Posted inClinical Updates Diabetes & Endocrinology news OB/GYN & Women's Health

Lifestyle Determinants and Metabolic Compensation in Pregnancies Complicated by Type 1 Diabetes: A Synthesis of the ENDIA Study and Recent Evidence

This review analyzes the lifestyle patterns of pregnant women with type 1 diabetes, synthesizing findings from the ENDIA study with recent evidence on nutritional adequacy, islet autoimmunity, and the molecular mechanisms of metabolic compensation.
Transitioning to Tubeless Automated Insulin Delivery: Clinical Insights from the RADIANT Trial and Contemporary Management of Type 1 Diabetes
Posted inClinical Updates Diabetes & Endocrinology news

Transitioning to Tubeless Automated Insulin Delivery: Clinical Insights from the RADIANT Trial and Contemporary Management of Type 1 Diabetes

This review synthesizes the landmark RADIANT trial findings, demonstrating the efficacy of transitioning patients from multiple daily injections to tubeless automated insulin delivery, while integrating broader evidence on genetic susceptibility and metabolic comorbidity management.
Addressing the Human Element: Why Psychological Barriers and Educational Gaps Limit the Efficacy of Diabetes Decision Support Systems
Posted inDiabetes & Endocrinology news Psychiatry

Addressing the Human Element: Why Psychological Barriers and Educational Gaps Limit the Efficacy of Diabetes Decision Support Systems

A randomized trial reveals that while automated decision support systems show marginal overall glycemic benefits in type 1 diabetes, personalized informative feedback significantly aids users with lower baseline knowledge. Success depends heavily on addressing diabetes-related distress and hypoglycemia worry.
Can We Predict Who Benefits? Baseline Insulin Secretion as a Gatekeeper for Abatacept Efficacy in Stage 1 T1D
Posted inDiabetes & Endocrinology Internal Medicine news

Can We Predict Who Benefits? Baseline Insulin Secretion as a Gatekeeper for Abatacept Efficacy in Stage 1 T1D

A post-hoc analysis demonstrates that baseline insulin secretion identifies responders to abatacept in Stage 1 T1D. High-secretors experienced a 15.8-month delay in disease progression and a 54% reduction in risk, providing the first evidence of successful immune intervention in the earliest stage of the disease.
High-Dose Oral Insulin Fails to Prevent Islet Autoimmunity: Primary Results from the POInT Randomized Trial
Posted inDiabetes & Endocrinology news Pediatrics

High-Dose Oral Insulin Fails to Prevent Islet Autoimmunity: Primary Results from the POInT Randomized Trial

The POInT trial demonstrated that high-dose daily oral insulin does not prevent islet autoantibodies in infants at high genetic risk for type 1 diabetes. Despite its safety, the primary endpoint was not met, though genotype-specific interactions suggest a need for more personalized prevention strategies.